Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.

doi:10.1111/cup.12364

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.

Journal of cutaneous pathology - 1 Sept 2014

Pearlstein Michelle V, Zedek Daniel C, Ollila David W, Treece Amanda, Gulley Margaret L, Groben Pamela A, Thomas Nancy E

Abstract excerpt

BACKGROUND: BRAF mutation status, and therefore eligibility for BRAF inhibitors, is currently determined by sequencing methods. We assessed the validity of VE1, a monoclonal antibody against the BRAF V600E mutant protein, in the detection of mutant BRAF V600E melanomas as classified by DNA pyrosequencing. METHODS: The cases were 76 metastatic melanoma patients with only one known primary melanoma who had had BRAF...

Topics

Antibodies, Monoclonal
Biomarkers, Tumor
Humans
Immunohistochemistry
Melanoma
Mutation
Proto-Oncogene Proteins B-raf
Sensitivity and Specificity
Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 24917033
DOI: 10.1111/cup.12364
PMCID: PMC4167935

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics